This brand name is authorized in Brazil, Canada, Ecuador, Hong Kong, Japan, Singapore, Turkey, United States, South Africa
The drug SOLIQUA contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Insulin glargine
UNII 2ZM8CX04RZ - INSULIN GLARGINE
|
|
Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. After injection, the acidic solution is neutralised leading to formation of a precipitate from which small amounts of insulin glargine are continuously released. |
|
2
Lixisenatide
UNII 74O62BB01U - LIXISENATIDE
|
|
Lixisenatide is a selective GLP-1 receptor agonist. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Lixisenatide stimulates insulin secretion when blood glucose is increased but not at normoglycaemia, which limits the risk of hypoglycaemia. In parallel, glucagon secretion is suppressed. In case of hypoglycaemia, the rescue mechanism of glucagon secretion is preserved. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| SOLIQUA Solution for injection in pre-filled pen (SoloStar) | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A10AE54 | Insulin glargine and lixisenatide | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AE Insulins and analogues for injection, long-acting |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 576720040062917, 576720040063017, 576720040063117, 576720040063217 |
| Country: CA | Health Products and Food Branch | Identifier(s): 02478293 |
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 150-MBE-0320, 151-MBE-0320 |
| Country: HK | Department of Health Drug Office | Identifier(s): 65637, 65638 |
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 3969501G1023 |
| Country: SG | Health Sciences Authority | Identifier(s): 15540P, 15542P |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699809951082, 8699809951099, 8699809951105, 8699809951112 |
| Country: US | FDA, National Drug Code | Identifier(s): 0024-5761 |
| Country: ZA | Health Products Regulatory Authority | Identifier(s): 52/32.16/0149, 52/32.16/0150 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
